# OnCo record nct07007559 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07007559/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07007559", "NCT07007559" ;
  schema:name "ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer"@en ;
  schema:alternateName "ASPEN-09-03"@en ;
  schema:description "A phase 2 trial of Evorpacept, Trastuzumab, Capecitabine, Eribulin, Gemcitabine and Vinorelbine in HER2-positive breast cancer, run by ALX Oncology Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07007559/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07007559> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-12-10" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/cd47-blockade/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/evorpacept/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/vinorelbine/> ;
  onco:companies <https://onco.cc/companies/alx-oncology/> .